Idera Pharmaceuticals (NASDAQ:IDRA) Share Price Passes Above 200-Day Moving Average of $0.26

Idera Pharmaceuticals, Inc. (NASDAQ:IDRAGet Rating)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.26 and traded as high as $0.51. Idera Pharmaceuticals shares last traded at $0.43, with a volume of 371,800 shares traded.

Analyst Ratings Changes

Separately, assumed coverage on shares of Idera Pharmaceuticals in a report on Tuesday. They set a “sell” rating on the stock.

Idera Pharmaceuticals Stock Performance

The company has a market cap of $26.50 million, a P/E ratio of -1.33 and a beta of 1.25. The firm’s 50 day moving average price is $0.33 and its 200-day moving average price is $0.26.

Idera Pharmaceuticals (NASDAQ:IDRAGet Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Idera Pharmaceuticals stock. Credit Agricole S A bought a new stake in Idera Pharmaceuticals, Inc. (NASDAQ:IDRAGet Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 200,000 shares of the biotechnology company’s stock, valued at approximately $92,000. Credit Agricole S A owned about 0.38% of Idera Pharmaceuticals at the end of the most recent quarter. Institutional investors own 12.18% of the company’s stock.

Idera Pharmaceuticals Company Profile

(Get Rating)

Aceragen, Inc is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Featured Articles

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with's FREE daily email newsletter.